AZ, Ionis hit by unexpected Wainua trial failure

AstraZeneca’s Wainua fails main goal in late-stage heart disease trial

STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug

AstraZeneca sees stock market value slump by more than £20bn after drug setback

AstraZeneca sees stock market value slump by more than £20bn after drug setback

AstraZeneca shares slide 9% after heart treatment disappoints in trial

Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial

Astrazeneca's stock dropped 9.1% after disappointing Phase 3 trial results for its heart drug Wainua. Over 140 weeks, the drug failed to sta